EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors

Blessie Elizabeth Nelson iD, Apostolia M Tsimberidou, Xueyao Fu, Siqing Fu, Vivek Subbiah, Anil K Sood, Jordi Rodon, Daniel D Karp, George Blumenschein, Scott Kopetz iD, Shubham Pant, Sarina A Piha-Paul iD

The Oncologist · 11.12.2023 · 28 (12) · 1100-e1292

DOI: 10.1093/oncolo/oyad158 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Oncologist, online erschienen am 13.06.2023. Verfasst von Blessie Elizabeth Nelson und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Mucositis, Neoplasms, Thrombocytopenia, Lymphopenia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NCI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Preclinical models suggest synergy between anti-angiogenesis therapy, mammalian target of rapamycin (mTOR), and histone deacetylase inhibitors to promote anticancer activity.

Methods

This phase I study enrolled 47 patients between April 2012 and 2018 and determined safety, maximum tolerated dose (MTD), and dose-limiting toxicities (DLTs) when combining bevacizumab, temsirolimus, and valproic acid in patients with advanced cancer.

Results

Median age of enrolled patients was 56 years. Patients were heavily pretreated with a median of 4 lines of prior therapy. Forty-five patients (95.7%) experienced one or more treatment-related adverse events (TRAEs). Grade 3 TRAEs were lymphopenia (14.9%), thrombocytopenia (8.5%), and mucositis (6.4%). Grade 4 TRAEs included lymphopenia (2.1%) and CNS cerebrovascular ischemia (2.1%). Six patients developed DLTs across 10 dose levels with grade 3 infection, rash, mucositis, bowel perforation, elevated lipase, and grade 4 cerebrovascular ischemia. The MTD was dose level 9 (bevacizumab 5 mg/kg days 1 and 15 intravenously (IV) plus temsirolimus 25 mg days 1, 8, 15, and 22 IV and valproic acid 5 mg/kg on days 1-7 and 15-21 per orally (PO)). Objective response rate (ORR) was 7.9% with confirmed partial response (PRs) in 3 patients (one each in parotid gland, ovarian, and vaginal cancers). Stable disease (SD) ≥+6 months was seen in 5 patients (13.1%). Clinical benefit state (CBR: PR + SD ≥+6 months) was 21%.

Conclusion

Combination therapy with bevacizumab, temsirolimus, and valproic acid was feasible, but there were numerous toxicities, which will require careful management for future clinical development (ClinicalTrials.gov Identifier: NCT01552434).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MucositisNeoplasmsThrombocytopeniaLymphopeniaFemaleHumansMiddle AgedBevacizumabValproic AcidAntineoplastic Combined Chemotherapy ProtocolsIschemiaMaximum Tolerated DoseSirolimus

Stichwörter der Autor:innen

HIF-1 alphabevacizumabclinical trialhistone deacetylase inhibitorstemsirolimusvalproic acidvascular endothelial growth factor

Substanzen

BevacizumabValproic AcidtemsirolimusSirolimus

Autor:innen und Institutionen

  • Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Thoracic and Head and Neck Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

ORCID-Profile: Blessie Elizabeth Nelson, Scott Kopetz, Sarina A Piha-Paul

Förderung

  • NCI NIH HHS
  • NIH HHS
  • NCI
  • NIH

Zitieren

APA

Nelson, B. E., Tsimberidou, A. M., Fu, X., Fu, S., Subbiah, V., Sood, A. K., Rodon, J., Karp, D. D., Blumenschein, G., Kopetz, S., Pant, S., & Piha-Paul, S. A. (2023). A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors. The Oncologist, 28(12), 1100-e1292. https://doi.org/10.1093/oncolo/oyad158

Vancouver

Nelson BE, Tsimberidou AM, Fu X, Fu S, Subbiah V, Sood AK, et al. A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors. The Oncologist. 2023;28(12):1100-e1292. doi:10.1093/oncolo/oyad158

BibTeX
@article{Nelson2023,
  author = {Nelson, Blessie Elizabeth and Tsimberidou, Apostolia M and Fu, Xueyao and Fu, Siqing and Subbiah, Vivek and Sood, Anil K and Rodon, Jordi and Karp, Daniel D and Blumenschein, George and Kopetz, Scott and Pant, Shubham and Piha-Paul, Sarina A},
  title = {A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors},
  journal = {The Oncologist},
  year = {2023},
  volume = {28},
  number = {12},
  pages = {1100--e1292},
  doi = {10.1093/oncolo/oyad158}
}
Kostenlos starten →